Journal article
Systemically administered PEDF against primary and secondary tumours in a clinically relevant osteosarcoma model
ML Broadhead, CR Dass, PFM Choong
British Journal of Cancer | Published : 2011
DOI: 10.1038/bjc.2011.410
Open access
Abstract
Background: Pigment epithelium-derived factor (PEDF) is an endogenous glycoprotein with a potential role as a therapeutic for osteosarcoma. Animal studies have demonstrated the biological effects of PEDF on osteosarcoma; however, these results are difficult to extrapolate for human use due to the chosen study design and drug delivery methods. Methods: In this study we have attempted to replicate the human presentation and treatment of osteosarcoma using a murine orthotopic model of osteosarcoma. The effects of PEDF on osteosarcoma cell lines were evaluated in vitro prior to animal experimentation. Orthotopic tumours were induced by intra-tibial injection of SaOS-2 osteosarcoma cells. Treatme..
View full abstractGrants
Funding Acknowledgements
We thank the Royal Australasian College of Surgeons, the Australian Orthopaedic Association and the St Vincent's Hospital Research Endowment Fund for their ongoing support. The Liddy Shriver Sarcoma Initiative generously funded this study. Matthew L Broadhead is supported by a Medical Postgraduate Scholarship, awarded by the National Health and Medical Research Council, Australia.